New hope for myeloma: experimental drug GR1803 takes on standard combo in phase 3 trial

NCT ID NCT07452198

Recruiting now Disease control Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Apr 03, 2026 · Last updated May 22, 2026 · Updated 6 times

Summary

This study tests whether a new drug called GR1803 works better than the standard treatment daratumumab (combined with pomalidomide and dexamethasone) for people with multiple myeloma that has returned or stopped responding after 1 to 3 prior treatments. About 358 adults with this blood cancer will be randomly assigned to receive either GR1803 or the standard combo. The main goal is to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITING

Tianjin, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA